How to Evaluate a Compounded GLP-1 Provider: What to Look for in 2026

*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting, stopping, or changing any medication.*

*Compounded semaglutide and tirzepatide are not FDA-approved. They are not equivalent to brand-name medications. Prescriva is a Management Services Organization (MSO). Clinical services are provided by independently licensed providers in our partner network.*

---

The compounded GLP-1 marketplace is changing fast. Regulatory proposals, pharmacy restrictions, and a wave of new telehealth providers have left many patients wondering: who can you actually trust?

That question matters more in 2026 than it ever has. Not every platform offering compounded semaglutide or tirzepatide operates the same way, and the differences can affect your safety, your legal access, and whether your medication is even legally dispensed.

This guide explains how to evaluate a provider, what questions to ask, and what the current regulatory landscape actually means for you as a patient.

---

Understanding 503A vs. 503B Compounding Pharmacies

To evaluate any compounded GLP-1 provider, you need to understand two categories of pharmacy that operate under very different legal frameworks.

503A pharmacies are state-licensed compounding pharmacies that prepare medications on a patient-specific basis. Each prescription is prepared for an individual patient based on a valid prescription from a licensed clinician. These pharmacies are regulated by state pharmacy boards, not directly by the FDA. They are not FDA-registered facilities and are not required to meet Current Good Manufacturing Practice (cGMP) standards. What they do offer: patient-specific prescriptions, state board oversight, and a legal framework that has remained unaffected by recent federal regulatory changes affecting larger compounders.

503B outsourcing facilities are larger-scale operations that are FDA-registered and subject to cGMP standards. Unlike 503A pharmacies, they can bulk compound and distribute medications without individual patient-specific prescriptions. They face stricter federal oversight and are directly subject to FDA decisions about which drug substances they may compound in bulk.

This distinction became critically important in 2026.

Prescriva sources compounded GLP-1 medications through 503A-licensed compounding pharmacies. This means every prescription is prepared for an individual patient following a clinician review, under state pharmacy board oversight.

---

The May 2026 FDA Regulatory Update

On May 1, 2026, the FDA published a formal proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List. The proposal reflects the FDA's finding that there is insufficient clinical need for outsourcing facilities to compound these drugs from bulk substances, given that FDA-approved versions are commercially available. You can read the announcement directly at [FDA.gov](https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list).

The public comment period closes June 29, 2026. The FDA will review submitted comments before issuing a final rule.

If the proposal is finalized, what does it mean for patients?

503B outsourcing facilities would lose their remaining pathway to bulk-compound GLP-1 medications. Patients who currently access compounded GLP-1s through 503B-sourced programs could face disruptions to their supply.

503A compounding pharmacies are not affected by this proposal. The patient-specific nature of 503A compounding places it in a separate legal category. Prescriptions filled by 503A pharmacies for individual patients with valid clinician prescriptions remain permissible under this regulatory framework as of May 2026.

If your current or prospective provider sources compounded GLP-1s through 503B facilities, this proposal directly affects your access. Understanding where your medication comes from is not a minor detail; it is a foundational question about continuity of care.

*Regulatory information reflects the landscape as of May 2026. Regulations may change. Verify current status with your provider and consult FDA.gov for the most recent guidance.*

---

Red Flags: What to Avoid

Not every telehealth platform operating in this space does so ethically or legally. Here are the warning signs that should prompt you to look elsewhere.

They cannot confirm their pharmacy's license status. Any reputable provider should be able to tell you which pharmacy prepares your medication and confirm that pharmacy holds a valid 503A state license. Vague answers like "we work with licensed partners" without specifics are a red flag.

There is no real clinician review. Some platforms approve prescriptions through questionnaire-only processes with no licensed clinician actually reviewing your health information. This is not adequate medical oversight for a prescription medication.

Pricing is unclear or changes at checkout. Hidden fees and bait-and-switch pricing are both a compliance concern and a sign that a provider is not operating with transparency.

They claim compounded semaglutide is the same as brand-name Ozempic or Wegovy. It is not. Compounded medications are not FDA-approved. They are not identical to brand-name products in the legal or regulatory sense. Any provider making this equivalence claim is misleading you.

There is no HIPAA-compliant data handling statement. Your health information is protected data under federal law. Providers should be explicit about how your information is stored, transmitted, and protected.

There is no clear cancellation or refund policy. Legitimate programs are transparent about what happens if you need to stop, pause, or dispute a charge. If this information is buried or absent, proceed with caution.

---

Green Flags: What Legitimate Providers Offer

Here is what separates trustworthy compounded GLP-1 programs from the rest.

Verified 503A pharmacy affiliation. The provider should be able to confirm which pharmacy they work with and that the pharmacy holds an active state compounding license. This information should not require repeated asking.

Named clinician review process. A licensed clinician (physician, nurse practitioner, or physician assistant) should review your health assessment before any prescription is issued. You should understand who is prescribing and what credentials they hold.

All-in transparent pricing. Medication, clinician consultation, and shipping costs should all be stated upfront before you submit any personal or payment information. You should not discover additional fees after enrollment.

Clear disclaimers about compounded medications. Reputable providers state clearly that compounded GLP-1 medications are not FDA-approved and are not equivalent to brand-name drugs. Transparency here is a mark of an ethical operation, not a weakness in their offer.

HIPAA compliance. Your health data should be protected by industry-standard security practices with explicit policies you can review.

Responsive patient support. You should have a clear path to reach someone with questions about your prescription, side effects, or billing. Healthcare should not be a one-way transaction.

---

Questions to Ask Any Provider

Before enrolling in a compounded GLP-1 program, get direct answers to these questions.

What pharmacy prepares my medication, and what is its license status? The answer should include the pharmacy name and confirmation of its active 503A state compounding license. A response that references "licensed compounding partners" without naming them is not sufficient.

Who reviews my health assessment before a prescription is issued? Confirm that a licensed clinician reviews your information before any prescription is generated, not just an automated screening tool.

What does the monthly price include? Confirm that medication, clinician consultation, and shipping are all included, or request an itemized cost breakdown before agreeing to anything.

What happens if I experience side effects? There should be a clear process for reaching a clinician or support team if you have concerns during treatment. Know this before you need it.

What is your cancellation policy? A legitimate program will give you a clear, direct answer. Read the policy before you enroll.

---

How Prescriva Approaches These Standards

Prescriva sources compounded semaglutide and tirzepatide through 503A-licensed compounding pharmacies. Every health assessment is reviewed by an independently licensed clinician in Prescriva's partner network before any prescription is issued. Prescriva does not use questionnaire-only approval processes.

Pricing is all-in: compounded semaglutide starts at $169/month and compounded tirzepatide starts at $269/month. These prices include medication, clinician consultation, and shipping.

Prescriva operates as Blue Oak Services LLC dba Prescriva, a Management Services Organization (MSO). Clinical services are provided by independently licensed providers in our partner network. Prescriva does not practice medicine.

Compounded medications dispensed through our program are not FDA-approved. They are not equivalent to brand-name Ozempic, Wegovy, or Zepbound. These distinctions are factual and every patient deserves to understand them before enrolling in any compounded GLP-1 program.

---

Making an Informed Decision

Healthcare decisions deserve careful evaluation, especially in a market where provider quality varies widely. The questions in this guide cover the most important ground.

A provider that cannot clearly answer where your medication comes from, who reviews your prescription, and what your total cost will be is a provider worth reconsidering. Transparency is not a premium service. It is the minimum standard for any program that takes your health seriously.

Do your research. Ask the hard questions. And consult a licensed healthcare provider before starting any new medication or treatment program.

*This content is for educational purposes only and does not constitute medical advice. Compounded GLP-1 medications are not FDA-approved and are not equivalent to brand-name products. Results vary. Consult your healthcare provider before starting any medication.*

*Clinical services are provided by independently licensed providers in Prescriva's partner network. Prescriva (Blue Oak Services LLC dba Prescriva) is a Management Services Organization and does not practice medicine.*